Chen et al. reported the pharmacokinetics of DTX-loaded PLGA-PEG NPs modified with anti-prostate-specific membrane antigen (PSMA) aptamer in LNCaP tumor-xenografted BALB/c mice for targeted delivery of DTX to prostate tumors [169]. The gene discussed is FOLH1; the disease is neoplasm.